These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8898435)

  • 1. Economic evaluation in gastrointestinal disease.
    Jönsson B; Karlsson G
    Scand J Gastroenterol Suppl; 1996; 220():44-51. PubMed ID: 8898435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Helicobacter pylori eradication therapy in duodenal ulcer disease.
    Jönsson B
    Scand J Gastroenterol Suppl; 1996; 215():90-5. PubMed ID: 8722390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.
    Barradell LB; McTavish D
    Pharmacoeconomics; 1993 Jun; 3(6):482-510. PubMed ID: 10146883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decision analysis of histamine H2-receptor antagonist maintenance therapy versus Helicobacter pylori eradication therapy: a randomised controlled trial in patients with continuing pain after duodenal ulcer.
    Tavakoli M; Prach AT; Malek M; Hopwood D; Senior BW; Murray FE
    Pharmacoeconomics; 1999 Oct; 16(4):355-65. PubMed ID: 10623364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin.
    Craig AM; Davey P; Malek M; Murray F
    Pharmacoeconomics; 1996 Jul; 10(1):79-92. PubMed ID: 10160472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model.
    Duggan AE; Tolley K; Hawkey CJ; Logan RF
    BMJ; 1998 May; 316(7145):1648-54. PubMed ID: 9603748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada.
    O'Brien B; Goeree R; Mohamed AH; Hunt R
    Arch Intern Med; 1995 Oct; 155(18):1958-64. PubMed ID: 7575049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost effectiveness of Helicobacter pylori eradication versus maintenance and episodic treatment in duodenal ulcer patients in Sweden.
    Unge P; Jönsson B; Stålhammar NO
    Pharmacoeconomics; 1995 Nov; 8(5):410-27. PubMed ID: 10160075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranitidine: a pharmacoeconomic evaluation of its use in acid-related disorders.
    Frampton JE; McTavish D
    Pharmacoeconomics; 1994 Jul; 6(1):57-89. PubMed ID: 10147354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group.
    Sonnenberg A; Schwartz JS; Cutler AF; Vakil N; Bloom BS
    Arch Intern Med; 1998 Apr; 158(8):852-60. PubMed ID: 9570170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapse prevention in reflux oesophagitis with regard to Helicobacter pylori status: a double-blind, randomized, multicentre trial to compare the efficacy of pantoprazole versus ranitidine.
    Adamek RJ; Behrendt J; Wenzel C
    Eur J Gastroenterol Hepatol; 2001 Jul; 13(7):811-7. PubMed ID: 11474311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.
    Wilde MI; McTavish D
    Drugs; 1994 Jul; 48(1):91-132. PubMed ID: 7525198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized, controlled study.
    Saberi-Firoozi M; Massarrat S; Zare S; Fattahi M; Javan A; Etaati H; Dehbashi N
    Am J Gastroenterol; 1995 Sep; 90(9):1419-23. PubMed ID: 7661161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of alternative Helicobacter pylori eradication strategies in the management of duodenal ulcer.
    O'Brien B; Goeree R; Hunt R; Wilkinson J; Levine M; William A
    Can J Gastroenterol; 1997; 11(4):323-31. PubMed ID: 9218858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer.
    Vakil N; Fennerty MB
    Am J Gastroenterol; 1996 Feb; 91(2):239-45. PubMed ID: 8607487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of new medical technology.
    Jönsson B
    Scand J Gastroenterol Suppl; 1994; 201():87-90. PubMed ID: 8047831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lansoprazole: an update of its place in the management of acid-related disorders.
    Matheson AJ; Jarvis B
    Drugs; 2001; 61(12):1801-33. PubMed ID: 11693467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of omeprazole and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the healing of duodenal ulcer: comparison with a historical control.
    Schütze K; Hentschel E; Hirschl AM
    Hepatogastroenterology; 1999; 46(28):2358-62. PubMed ID: 10521998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rabeprazole: an update of its use in acid-related disorders.
    Carswell CI; Goa KL
    Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.
    Langtry HD; Wilde MI
    Drugs; 1998 Sep; 56(3):447-86. PubMed ID: 9777317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.